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Peyronie’s disease (PD) is a connective tissue disorder where formation of fibrous 
plaques in tunica albuginea (TA) and erectile tissue can result in penile deformity, pain, 
and erectile dysfunction. Fibrosis, its major pathological manifestation, arises from 
fibroblast proliferation and accumulation of extracellular matrix; PD progresses with 
formation of plaques or even ectopic calcification having the appearance of scar tissue, 
which prevent TA expansion during erections. The mechanisms underpinning PD are 
unclear, and relatively little is known about the disease itself. To date corrective surgery 
is the sole effective treatment. A greater understanding of PD pathophysiology at the 
molecular level has the potential to help develop novel medical therapeutic approaches.
The aim of this study was to investigate the activation of the apoptotic intrinsic 
apoptotic pathway in plaques from PD patients. Tunica albuginea from either PD and 
control patients were assessed for the expression of bax, bcl-2, caspase 9 and 3 using 
immunohistochemistry, and by measurement of apoptotic cells using TUNEL assay. 
Bax overexpression was observed in metaplasic bone tissue, in fibroblasts and in myofi-
broblast of plaques from PD patients. Little or no bcl-2 immunostaining was detected 
in samples from either patients or controls. Caspase 3 immunostaining was very strong 
in fibrous tissue, in metaplasic bone osteocytes and in primary ossification center oste-
oblasts. Moderate caspase 9 immunostaining was seen in fibrous cells plaques and 
in osteocytes and osteoblasts of primary ossification centers from PD patients. Con-
trol samples were negative for caspase 9 immunostaining. In PD patients the TUNEL 
immunoassay showed intense immunostaining of fibroblasts and myofibroblasts, the 
absence of apoptotic cells in metaplasic bone tissue and on the border between fibrous 
and metaplasic bone tissue. 
Apoptotic cell death occurs in stabilized PD plaques and is partly induced by the 
intrinsic mitochondrial pathway. The present findings can have clinical implications 
and may help devise improved treatment strategies. A therapeutic approach aimed at 
enhancing apoptosis-inducing molecules would at least help delay the progression of 
PD. Identification of target molecules for gene construct or biological or chemical rea-
gent delivery to target sites could contribute to induce  PD plaque stabilization. 
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